The same approach was used in a improved trial conducted with the Synchrovax SEM plasmid DNA vaccine containing a plasmid pSEM that encodes 4 peptide epitope sequences, Melan-A (26-35), Melan-A (31-96), tyrosinase (1) (2) (3) (4) (5) (6) (7) (8) (9) , and tyrosinase (369-377), resulting in antigen-specific immunity even though not induce regression of established disease [145] .